Verona Pharma - RNS (29th September 2015)

Verona Pharma (VRP) - Update on RPL554 Clinical Study

The RNS released this morning looks encouraging, see below:

---------------------------------  Start of RNS Summary  ---------------------------------------------------------------------------------------------

29 Sep 2015 07:00:00

Verona Pharma PLC

Verona Pharma plc

("Verona Pharma" or the "Company")

 Positive headline data from RPL554 clinical study in COPD patients

New suspension formulation is well tolerated; results signal marked improvement in lung function 

RPL554 remains on track for entry into Phase IIb clinical trials in 2H 2016

29 September 2015, Cardiff ? Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces encouraging positive headline data of the third and final part (part C) of a randomised, double blind, placebo controlled Single Ascending Dose (SAD) / Multiple Ascending Dose (MAD) clinical study in stable chronic obstructive pulmonary disease (COPD) patients. This study uses a new proprietary and commercially scalable nebulised suspension formulation of the Company?s lead pipeline drug, RPL554.^1,2 The primary objective of this part of the study was to show the safety and tolerability of the new drug formulation in stable COPD patients with moderate severity of disease.³ Measurement of lung function using FEV1⁴ was included. Evaluation of the full data set is ongoing and will be presented in an appropriate scientific, peer-reviewed forum at a later date.

Highlights: Part C of study in 32 stable COPD patients with moderate disease severity³

• Primary objective of study met: Drug formulation well tolerated at all dose levels; No serious adverse events reported
  • Adverse event profile similar to that seen with placebo
  • Absence of gastro-intestinal or cardiovascular adverse events

• RPL554 caused pronounced improvement in lung function
  • Mean peak FEV1 increase ranged from 199ml to 257ml versus placebo
  • Extent of bronchodilation exceeds that seen in earlier studies with original proof of concept formulation

• Data continue to support twice daily dosing regimen with RPL554

• Data consistent with that from earlier part A and B of study in healthy volunteers
• Evaluation of the full data set from this trial is ongoing

-------------------------------------------  End of RNS Summary  ----------------------------------------------------------------------------------

The Full announcement can be seen HERE!

The Sharescope price graph is also very interesting...

Verona Pharma - SharePrice Graph (10 months)

Summary

The news-flow has been positive for Verona Pharma, in relation to RPL554 and it could eventually cause this share to "take off". As ever, it's a matter of judgement as to whether to invest (and when)... take a look and let me know what you think.

Mick (29th September 2015)

Dart Group - Preliminary Results (16th July 2015)

Dart Group (DTG) - Pre-Tax Profit Up

The preliminary results from Dart Group look quite impressive this morning. The key points are as follows:

• underlying pre-tax profits of £57.2m for the year to the end of March - up 36% compared to last year
• Group Turnover up by 12% to £1,253.2m - underlying operating profits were up 3% at £50.6m, this reflected improved trading and continued investment in Darts Leisure Travel business.
• Allowing for an exceptional provision of £17.0m, in relation to potential passenger compensation claims (for historical flight delays under Regulation (EC) No 261/2004) - group profit before tax (pbt) fell 5% to £40.2m.
• Leisure Travel turnover growth of 14% to £1,101.5m (2014: £967.0m) reflected an 8% increase in passenger sectors flown, in line with increased seat capacity. There was also a 20% increase in package holiday customers.
• Distribution & Logistics added £151.7m of turnover (2014: £153.2m).

Link to full results HERE

AGA - Possible Offer (17th June 2015)

Aga Rangemaster Group (AGA) - Possible Offer

Those of us following AGA Rangemaster will be interested in the RNS announcement today, as follows:
-------------------------------------------------------------------------------------------------------------------

RNS Number : 4628Q

Aga Rangemaster Group PLC

17 June 2015

Strictly Private & Confidential

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CODE. THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER MIGHT BE MADE

FOR IMMEDIATE RELEASE

17 June 2015

AGA Rangemaster Group plc ("AGA" or the "Company")

Statement regarding Possible Offer

The Company notes the recent movement in the Company's share price and confirms that it is in discussions with The Middleby Corporation ("Middleby") regarding a possible cash offer for the Company.

There can be no certainty that any formal offer will be made, or as to the terms of any offer.

In accordance with Rule 2.6(a) of the Code, Middleby is required, by no later than 5.00 p.m. on 15 July 2015, to either announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or announce that it does not intend to make such an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline may be extended with the consent of the Takeover Panel in accordance with Rule 2.6 of the Code.

In accordance with Rule 2.10 of the Code, the Company confirms that, as at the date of this announcement, it has 69,264,223 ordinary shares of 46 7/8p nominal value each in issue and admitted to trading on the London Stock Exchange's main market for listed securities. The International Securities Identification Number of the ordinary shares is GB00B2QMX606. 

In accordance with Rule 26.1 of the Code, a copy of this announcement will be available on the Company's website at www.agarangemaster.com. 

The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

-------------------------------------------------------------------------------------------------------------------

The affect on the share price was a gain of 31.25p (+30.0%) today, as can be seen from the graph below...

Speedy Hire (SDY) : 12th May 2015

Will Speedy Hire "Speed Up"?

Speedy Hire (SDY), issued its Preliminary Results today (12th May 2015). These show that things are progressing well at the plant hire firm (see below)...

Couple these results with the "Breakout" from the recent downtrend and DIY-Investors might well benefit from taking a closer look at Speedy Hire.

What do think of the prospects for Speedy Hire over the next 12 months?

Mick (12th May 2015)

This May Be Worth Checking (29th April 2015)

Is Exillon Energy (EXI) Under-Valued?

If you have a look at the Sharescope Graph and Key Metrics (see below), you may see what I mean...

The Key Points (IMHO) are:

• Low PTBV (0.51)
• Low PEG (0.14)
• Modest PCF (3.411)
• Growing Profit
• Growing Turnover
• Good TA (strong OBV)
• Increasing oil production (see recent RNS releases [not shown])

As ever, you'll need to DYOR but the results (expected tomorrow) should be worth analysing.

What do you think?

Mick (29th April 2015)

Cenkos - Breakout (26th March 2015)

Cenkos Securities (CNKS) - Trend Breakout

Join the DIY-Investors Inner Circle to keep up to date with techniques for "Picking Winning Shares".

Any Thoughts (Fri 6th March 2015)?

PFD - Lateral Breakout?

Premier Foods (19th January 2015)

The chart of Premier Foods has been on my radar screen since the Christmas period, as the price gently slid (laterally) out through the gently sloping downtrend line that has been in place since last September. This line itself marked a more shallow downtrend than the longer running line, in place since April 2014 (see graph below)...

I'm interested in the 50 day moving avergae (blue line), which has just started to turn up and the fact that the downtrend on the OBV has also been broken (to the upside). Supporting this are buy signals on both ADX indicators (annotated on the graph).

Key Metrics

The key points, from the Key metrics (above) are:

• Low PSR (0.18)
• Low PE(pr) of 4.7
• Low PCF & P/FCF (1.559 & 1.646 [respectively])

However, don't forget to check out the share dilution as a result of the placing and rights issue (completed in April 2014).

RNS (Management Statement)

The following RNS states that Q4 Management Statement will be released on Friday 23rd January 2015. I also note that there is a link to a webinar... I might just listen in!

16 January 2015

Notification of Management Statement

Premier Foods' Quarter 4 Management Statement for the quarter to 31 December 2014 and summary results for the 12 months to 31 December 2014 will be released at 7.00am on Friday, 23 January 2015.  This will be followed by a webinar for investors and analysts at 9:00am, hosted by Gavin Darby, CEO and Alastair Murray, CFO. The details are outlined below.

Webinar registration link:

www.premierfoods.co.uk/investor-relations/

Summary

Notwithstanding the mixed signals, it may be worth keeping a close watch on PFD in the next few months. What do you think?

Mick (19th January 2015)